Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1506 participants.
Also called NCT02866175
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,506 participants
- Registry
-
NCT02866175 -
2016-002683-14
-
- Other papers using this trial's data
- Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis
- Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Austria, Belgium, France, Germany, Hungary, Italy, Lithuania, Netherlands, Poland, Portugal, Romania, Serbia, South Korea, Spain, Switzerland, Taiwan, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02866175. Randomized; no masking; primary purpose treatment. Start 2017-02-24 (actual); primary completion 2019-06-06 (actual). Results posted on 2020-05-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
- Acronym
- ENTRUST-AF-PCI
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Edoxaban
- Intervention (Drug)
- Clopidogrel
- Intervention (Drug)
- Prasugrel
- Intervention (Drug)
- Ticagrelor
- Intervention (Drug)
- Vitamin K antagonist
- Lead sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Record details
- Record id
cardio:ct-nct02866175- Content hash
46f5586fc86a31689d4896159a711c4a1ab7c65468fa9d013e5439a243a6bfe9